GlassScriptPhysician profile
Uday Desai
NPI 1770537615
$6,246.68
in general payments reported to CMS, 2019-2025
44 companies · $1,971 in 2025
The $1,971 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $400 · 2021: $534 · 2022: $1,011 · 2023: $762 · 2024: $1,003 · 2025: $1,971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,555 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,555.48 |
| Education | $181.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $677.38 | 2019-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $639.83 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $554.10 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $424.07 | 2020-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $413.39 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $283.67 | 2019-2025 | Rayaldee |
| Amgen INC. | $232.18 | 2019-2025 | Tavneos, Krystexxa |
| Merck Sharp & Dohme LLC | $224.26 | 2024-2025 | Prevymis |
| Aurinia Pharma U.S., INC. | $223.14 | 2021-2025 | Lupkynis |
| Veloxis Pharmaceuticals, INC. | $212.85 | 2020-2025 | Envarsus |
| Novartis Pharmaceuticals Corporation | $211.39 | 2023-2025 | |
| Travere Therapeutics, INC. | $175.66 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.81 | 2021-2025 | |
| Mallinckrodt Enterprises LLC | $141.28 | 2019 | |
| Glaxosmithkline, LLC. | $140.91 | 2021-2024 | Benlysta, Jesduvroq |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $135.01 | 2021-2024 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $134.64 | 2019-2024 | Velphoro |
| Ardelyx, INC. | $122.27 | 2024-2025 | Ibsrela |
| Recordati_rare_diseases_inc. | $113.00 | 2022-2023 | Cystadrops |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.63 | 2024-2025 | Jardiance |
| American Regent | $80.13 | 2023 | Injectafer |
| Alnylam Pharmaceuticals INC. | $68.76 | 2021-2023 | Givlaari |
| Alexion Pharmaceuticals, INC. | $66.41 | 2025 | Ultomiris |
| Leadiant Biosciences, INC. | $63.65 | 2022-2025 | Cystaran |
| Renalytix Ai, INC. | $63.39 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Eusa Pharma (US) LLC | $63.35 | 2022 | |
| Ani Pharmaceuticals, INC. | $52.99 | 2022-2024 | Purified Cortrophin Gel |
| Averitas Pharma INC. | $50.71 | 2024 | Qutenza |
| Octapharma USA, INC. | $46.02 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $45.31 | 2025 | Keveyis |
| Baxter Healthcare | $44.41 | 2020-2023 | Renal - Acute |
| Chiesi USA, INC. | $40.20 | 2025 | Elfabrio |
| Lilly USA, LLC | $37.54 | 2023 | Jardiance |
| Amicus Therapeutics, INC. | $35.00 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $26.18 | 2025 | Empaveli |
| Cycle Pharmaceuticals INC | $21.27 | 2024 | Tiopronin |
| Takeda Pharmaceuticals U.S.A., INC. | $17.35 | 2021 | |
| Medtronic, INC. | $16.62 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $16.15 | 2020 | |
| Kyowa Kirin, INC. | $15.97 | 2023 | |
| Arbor Pharmaceuticals, INC. | $15.44 | 2019 | |
| Horizon Therapeutics Plc | $14.00 | 2019 | |
| Shield Therapeutics INC | $13.80 | 2023 | Accrufer |
| Daxor Corporation | $13.56 | 2024 | Bva-100 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uday Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.